MedPath

厦门特宝生物工程股份有限公司

Ownership
-
Established
1996-08-07
Employees
1.9K
Market Cap
-
Website
https://www.amoytop.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

30

NMPA:30

Drug Approvals

Inpegsomatropin Injection

Product Name
益佩生
Approval Number
国药准字S20250028
Approval Date
May 27, 2025
NMPA

Inpegsomatropin Injection

Product Name
益佩生
Approval Number
国药准字S20250027
Approval Date
May 27, 2025
NMPA

Inpegsomatropin Injection

Product Name
益佩生
Approval Number
国药准字S20250029
Approval Date
May 27, 2025
NMPA

Inpegsomatropin Injection

Product Name
益佩生
Approval Number
国药准字S20250026
Approval Date
May 27, 2025
NMPA

Inpegsomatropin Injection

Product Name
益佩生
Approval Number
国药准字S20250025
Approval Date
May 27, 2025
NMPA

Telpegfilgrastim Injection

Product Name
珮金
Approval Number
国药准字S20230039
Approval Date
Jun 30, 2023
NMPA

Telpegfilgrastim Injection

Product Name
珮金
Approval Number
国药准字S20230037
Approval Date
Jun 30, 2023
NMPA

Telpegfilgrastim Injection

Product Name
珮金
Approval Number
国药准字S20230036
Approval Date
Jun 30, 2023
NMPA

Telpegfilgrastim Injection

Product Name
珮金
Approval Number
国药准字S20230038
Approval Date
Jun 30, 2023
NMPA

Peginterferon alfa-2b Injection

Product Name
派格宾
Approval Number
国药准字S20160001
Approval Date
May 24, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.